Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Can Gartner’s Massive Share Buyback Reverse Its Stock Decline?

Dieter Jaworski by Dieter Jaworski
September 15, 2025
in Analysis, Tech & Software, Value & Growth
0
Gartner Stock
0
SHARES
164
VIEWS
Share on FacebookShare on Twitter

Gartner Inc. has significantly expanded its share repurchase initiative by an additional $1 billion, bringing the total program to $7 billion. This substantial move, announced on September 10, represents a powerful statement from management that it believes the market is significantly undervaluing the IT consulting giant. The critical question for investors is whether this financial maneuver can halt the stock’s persistent downward trajectory.

The timing of this decision is crucial. Gartner’s shares have faced considerable pressure, having lost more than half their value since reaching a peak in February. The stock is currently trading near €208, struggling to regain momentum. By reducing the number of outstanding shares, the buyback program aims to mechanically boost earnings per share—a classic approach to enhancing shareholder value despite market headwinds.

Mixed Financial Signals and Market Reaction

Recent quarterly performance reveals a complex financial picture. While Gartner surpassed analyst expectations for adjusted earnings per share in the second quarter, reporting $3.53 compared to the projected $3.38, the company fell slightly short on revenue. Its $1.66 billion in sales came in just below market forecasts. This mixed performance has created divergent views among investment analysts covering the stock.

The analyst community remains predominantly cautious. Goldman Sachs maintains an optimistic outlook with a “Buy” rating and a $457 price target. However, this bullish stance contrasts with more conservative assessments. RBC Capital Markets initiated coverage just last week with a “Sector Perform” rating and a $263 target. Several other firms, including Wells Fargo, BMO Capital Markets, and Morgan Stanley, have recently revised their expectations downward.

Should investors sell immediately? Or is it worth buying Gartner?

Leadership Confidence and Strategic Positioning

Amid these challenges, internal signals suggest management confidence. CEO Eugene Hall, along with other company executives, increased their personal holdings in August—a move typically interpreted as a vote of confidence in the company’s strategic direction. Concurrently, Gartner continues to advance its product innovation pipeline, including “AskGartner,” an AI-powered platform designed to provide clients with faster access to critical insights.

The technology sector is undergoing profound transformation, and Gartner’s own research highlights the significance of emerging trends. The firm’s recent “Hype Cycle for Emerging Technologies” positions AI agents at the peak of innovation. Whether Gartner can effectively capitalize on these same technologies to drive its own growth remains a pivotal question.

While the massive share repurchase may provide short-term price support and demonstrate fiscal confidence, Gartner’s long-term success will ultimately depend on proving that its advisory services remain indispensable in an increasingly AI-driven marketplace.

Ad

Gartner Stock: Buy or Sell?! New Gartner Analysis from February 8 delivers the answer:

The latest Gartner figures speak for themselves: Urgent action needed for Gartner investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Gartner: Buy or sell? Read more here...

Tags: Gartner
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Incyte Stock

Incyte Investors Await Pivotal FDA Ruling on Dermatology Drug

MP Materials Stock

MP Materials Navigates Strategic Gains Amid Financial Headwinds

iShares U.S. Aerospace & Defense ETF Stock

Concentrated Exposure: Analyzing the iShares U.S. Aerospace & Defense ETF

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com